Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00177554
Status:
COMPLETED
Last Update Posted:
2008-05-29
First Post:
2005-09-13
Brief Title:
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
Status:
COMPLETED
Status Verified Date:
2008-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma
Detailed Description:
Patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized phase II study evaluating up front therapy with CHOP-R x 3 cycles followed by zevalin and 4 additional weeks of rituxanThe complete response will be determined by combining IWC criteria and PET scanningSecondary objectives include PET-CT conversion rate frequency and severity of adverse events duration of complete remission and time to next lymphoma therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None